Treatment of overactive bladder with botulinum toxin type B: a pilot study.
The purpose of this study was to determine the efficacy and safety of botulinum toxin type B (BTX-B/Myobloc) in the treatment of patients with overactive bladder. This open-label dose-escalation study enrolled 15 female patients with urinary frequency with or without incontinence. The BTX-B doses used in this study were 2500, 3750, 5000, 10 000 and 15 000 units. Response was defined as a subjective improvement in frequency, urgency and incontinence symptoms. A paired t-test of the pre/post frequency difference indicates that these 15 patients experienced an average of 5.27 fewer frequency episodes per day after treatment with BTX-B. The p value for the paired t-test was <0.001. The longest duration effect was 3 months using 10 000-15 000 units of BTX-B. The correlation between dose and duration was very significant, with a correlation coefficient = 0.96, p<0.001. Based on these findings, we feel the use of botulinum toxin to treat patients with overactive bladder warrants further study.
Dykstra
Dennis
D
Department of Physical Medicine and Rehabilitation, University of Minnesota, MMC 297, MN 55455, Minneapolis, USA. dykst001@tc.umn.edu
Enriquez
Al
A
Valley
Michael
M
D000368:Aged; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D005260:Female; D006801:Humans; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome; D014555:Urination Disorders / Q000188:drug therapy*
C096323:rimabotulinumtoxinB; D008666:Metalloendopeptidases; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A